Amgen: Q4 EPS up 26% at 4.36 dollars
(CercleFinance.com) - On Monday evening Amgen reported Q4 2021 non-GAAP EPS that is up 26% at 4.
36 dollars, with an adjusted operating margin that improved 4.7% to 47.8%.
The healthcare group's total revenues rose 3% to 6.8 billion dollars, driven by higher revenues from its manufacturing collaboration with Eli Lilly on Covid-19, while its product sales fell 1%.
Amgen reported FY adjusted EPS that is up 6% at 17.10 dollars, with revenues increasing 2% to 26 billion dollars, despite flat product sales.
Copyright (c) 2022 CercleFinance.com. All rights reserved.